Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QDWDN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SC-005
|
|||||
| Synonyms |
SC-005
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Histologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.
|
||||
| Administration Dosage |
SC-005 intravenous (IV) (various doses and dose regimens)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03316794 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | ||||
| Primary Endpoint |
Number of Participants with Dose-limiting Toxicities (DLTs) [Time Frame: Minimum 21 days]
|
||||
| Other Endpoint |
QTcF Change from Baseline [Time Frame: Up to approximately 9 weeks]; Area Under the Plasma Concentration-time Curve (AUC); Clinical benefit rate (CBR); Maximum plasma concentration observed (Cmax); Overall Survival (OS); Observed Plasma Concentrations at Trough; Duration of Clinical Benefit (DOCB)
|
||||